Myasthenia Gravis - Drug Pipeline Landscape, 2023
Description
Myasthenia Gravis - Drug Pipeline Landscape, 2023
Myasthenia gravis is a chronic autoimmune neuromuscular condition that causes muscle weakness and severe fatigue. It causes weakness in the skeletal muscles, which are the muscles your body uses for movement.
Myasthenia gravis is caused by a breakdown in the normal communication between nerves and muscles.
Healthcare professional checks neurological health by testing reflexes, muscle strength, muscle tone etc. Ice pack test, antibody tests, imaging scans and electromyogram can also be used for diagnosis.
Myasthenia gravis treatments include medications, monoclonal antibodies, iv immunoglobulin (ivig), plasma exchange (plasmapheresis) and surgery.
The companies active in development of Myasthenia Gravis Drugs are Ahead Therapeutics, Alexion Pharmaceuticals, AnTolRx, Argenx, Cabaletta Bio etc.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the treatment of Myasthenia Gravis treatment such as Efgartigimod IV, amifampridine, batoclimab and others. Key players involved in the development of therapies to treat Myasthenia gravis are Alexion Pharmaceuticals, argenx, UCB Biopharma and others. One drug is in Pre-Registration, 10+ drugs are in Phase III and 6 drugs are in Phase II clinical trials and some other drugs are under Phase I, Phase 0, preclinical, discovery and unknown stages of development. In Sep 2022, argenx SE submitted Biologics License Application (BLA) to the U.S. FDA for SC efgartigimod. In Nov 2022, UCB announced that US FDA has accepted to review the NDA for zilucoplan.
Report Highlights
Global Insight Service's, Myasthenia Gravis - Drug Pipeline Landscape, 2023 report provides an overview of the Myasthenia gravis pipeline drugs. This report covers detailed insights on Myasthenia Gravis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Myasthenia Gravis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
To plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Myasthenia gravis is a chronic autoimmune neuromuscular condition that causes muscle weakness and severe fatigue. It causes weakness in the skeletal muscles, which are the muscles your body uses for movement.
Myasthenia gravis is caused by a breakdown in the normal communication between nerves and muscles.
Healthcare professional checks neurological health by testing reflexes, muscle strength, muscle tone etc. Ice pack test, antibody tests, imaging scans and electromyogram can also be used for diagnosis.
Myasthenia gravis treatments include medications, monoclonal antibodies, iv immunoglobulin (ivig), plasma exchange (plasmapheresis) and surgery.
The companies active in development of Myasthenia Gravis Drugs are Ahead Therapeutics, Alexion Pharmaceuticals, AnTolRx, Argenx, Cabaletta Bio etc.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the treatment of Myasthenia Gravis treatment such as Efgartigimod IV, amifampridine, batoclimab and others. Key players involved in the development of therapies to treat Myasthenia gravis are Alexion Pharmaceuticals, argenx, UCB Biopharma and others. One drug is in Pre-Registration, 10+ drugs are in Phase III and 6 drugs are in Phase II clinical trials and some other drugs are under Phase I, Phase 0, preclinical, discovery and unknown stages of development. In Sep 2022, argenx SE submitted Biologics License Application (BLA) to the U.S. FDA for SC efgartigimod. In Nov 2022, UCB announced that US FDA has accepted to review the NDA for zilucoplan.
Report Highlights
Global Insight Service's, Myasthenia Gravis - Drug Pipeline Landscape, 2023 report provides an overview of the Myasthenia gravis pipeline drugs. This report covers detailed insights on Myasthenia Gravis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Myasthenia Gravis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
To plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Table of Contents
125 Pages
- 1. Introduction
- 1.1 Myasthenia Gravis - Pipeline Drugs, 2023-Coverage
- 2. Disease Overview - Myasthenia Gravis
- 2.1 Causes
- 2.2 Signs and Symptoms
- 2.3 Diagnosis
- 2.4 Disease Management
- 3. Myasthenia Gravis - Pipeline Drugs Development - Overview
- 3.1 Comparative Analysis by Stage of Development
- 3.2 Number of Products under Development by Companies, 2023
- 3.3 Products under Development by Companies, 2023
- 4. Assessment of Therapeutics
- 4.1 Assessment by Target
- 4.2 Assessment by Mechanism of Action
- 4.3 Assessment by Molecule Type
- 4.3 Assessment by Route of Administration
- 5. Drug Profiles
- 5.1 Late Stage Drugs-Pre-Registration
- 5.1.1 Efgartigimod IV
- 5.2 Clinical Stage Drugs-Phase III
- 5.2.1 Amifampridine
- 5.2.2 Batoclimab
- 5.2.3 Efgartigimod SC
- 5.2.4 HBM9161
- 5.2.5 Hizentra
- 5.2.6 Inebilizumab
- 5.2.7 Nipocalimab
- 5.2.8 Pozelimab + Cemdisiran
- 5.2.9 Ravulizumab
- 5.2.10 Rozanolixizumab
- 5.2.11 Satralizumab
- 5.2.12 Tolebrutininb
- 5.2.13 zilucoplan (RA101495)
- 5.3 Clinical Stage Drugs-Phase II
- 5.3.1 ALXN2050
- 5.3.2 DAS-001
- 5.3.3 Descartes-08
- 5.3.4 Mezagitamab
- 5.3.5 NMDP-01/NMD-670
- 5.3.6 RC18
- 5.4 Clinical Stage Drugs-Phase I
- 5.4.1 KIMS-002
- 5.4.2 RLYB116
- 5.5 Clinical Stage Drugs-Phase 0
- 5.5.1 CT103A cells
- 5.6 Early Stage Drugs-Preclinical
- 5.6.1 MuSK-CAART
- 5.6.2 Myasthenia Program
- 5.6.3 Oxaloacetate
- 5.6.4 TOL2
- 5.7 Early Stage Drugs-Discovery
- 5.7.1 AT_1616
- 5.8 Early Stage Drugs-Unknown
- 5.8.1 KPL-404
- 6. Key Regulatory Designations
- 7. Key Deals
- 8. Key Upcoming Milestones
- 9. Key Companies Involved
- 9.1 Ahead Therapeutics
- 9.2 Alexion Pharmaceuticals
- 9.3 AnTolRx
- 9.4 Argenx
- 9.5 Cabaletta Bio
- 9.6 Cartesian Therapeutics
- 9.7 Catalyst Pharmaceuticals, Inc.
- 9.8 CSL Behring
- 9.9 DAS-MG, Inc
- 9.10 Harbour BioMed (Guangzhou) Co. Ltd.
- 9.11 Hoffmann-La Roche
- 9.12 Horizon Therapeutics
- 9.13 Immunovant Sciences GmbH
- 9.14 Johnson & Johnson
- 9.15 KIMS Pharmaceutical Co Ltd
- 9.16 Kiniksa Pharmaceuticals Corp
- 9.17 Nanjing IASO Biotherapeutics Co.,Ltd
- 9.18 NMD Pharma
- 9.19 Rally Bio
- 9.20 Regeneron Pharmaceuticals
- 9.21 RemeGen Co., Ltd.
- 9.22 Sanofi
- 9.23 Takeda
- 9.24 Terra Biological LLC
- 9.25 Toleranzia
- 9.26 UCB Pharma
- 10. Dormant Drugs
- 10.1 Inactive Drugs
- 10.2 Discontinued Drugs
- 11. Appendix
- List of Tables
- Table 1. 2 Number of Products under Development by Companies
- Table 1. 3 Products under Development by Companies
- Table 1. 4 Products by Targets
- Table 1. 5 Products by Mechanism of Action
- Table 1. 6 Products by Molecule Type
- Table 1. 7 Products by Route of Administration
- Table 2. 1 Clinical Trial Details - Esreboxetine/Pfizer
- Table 2. 2 Clinical Trial Details - Amifampridine/ Catalyst Pharmaceuticals, Inc.
- Table 2. 3 Clinical Trial Details - Batoclimab/ Immunovant Sciences GmbH
- Table 2. 4 Clinical Trial Details - Efgartigimod SC/Argenx
- Table 2. 5 Clinical Trial Details - HBM9161/Harbour BioMed (Guangzhou) Co. Ltd.
- Table 2. 6 Clinical Trial Details - Hizentra/CSL Behring
- Table 2. 7 Clinical Trial Details - Inebilizumab/Horizon Therapeutics
- Table 2. 8 Clinical Trial Details - Nipocalimab/ Johnson & Johnson.
- Table 2. 9 Clinical Trial Details - Pozelimab + Cemdisiran/ Regeneron Pharmaceuticals Inc
- Table 2. 10 Clinical Trial Details - Ravulizumab/Alexion Pharmaceuticals
- Table 2. 11 Clinical Trial Details - Rozanolixizumab/UCB Pharma
- Table 2. 12 Clinical Trial Details - Satralizumab/Hoffmann-La Roche
- Table 2. 13 Clinical Trial Details - Tolebrutininb/Sanofi
- Table 2. 14 Clinical Trial Details - Zilucoplan/UCB Pharma
- Table 2. 15 Clinical Trial Details - ALXN2050/Alexion Pharmaceuticals
- Table 2. 16 Clinical Trial Details - DAS-001/DAS-MG, Inc
- Table 2. 17 Clinical Trial Details - Descartes-08/Cartesian Therapeutics
- Table 2. 18 Clinical Trial Details - Mezagitamab/Takeda
- Table 2. 19 Clinical Trial Details - RC18/RemeGen Co., Ltd.
- Table 2. 20 Clinical Trial Details - CT103A cells/Nanjing IASO Biotherapeutics Co.,Ltd.
- Table 3. 1 Regulatory Designations
- Table 4. 1 Inactive Drugs
- Table 4. 2 Discontinued Drugs
- List of Figures
- Figure 1. 1 Number of Products under Development for Myasthenia Gravis, 2023
- Figure 1. 2 Products by Top 5 Targets and Stage of Development for Myasthenia Gravis, 2023
- Figure 1. 3 Products by Top 5 Mechanism of Action and Stage of Development for Myasthenia Gravis, 2023
- Figure 1. 4 Products by Top 5 Molecule Type and Stage of Development for Myasthenia Gravis, 2023
- Figure 1. 5 Products by Top 5 Route of Administration and Stage of Development for Myasthenia Gravis, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
